Authors
Latest:
Addressing Patients' Concerns With BiosimilarsDrs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns with biosimilars and provide take-home messages to clinicians utilizing biosimilars.
Latest:
2021 Acne Updates: New Drugs and ResearchA presentation from Maui Derm Live 2021 featured insights on new drugs and data in acne.
Latest:
Q&A: Diagnostic and Therapeutic Pearls for Pediatric DermatologyMancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.
Latest:
Rashmi Sarkar, MD, FAMS: Vitiligo and StigmaSarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.
Latest:
Cyltezo Biosimilar Launches Today in the USBoehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.
Latest:
The JAK Inhibitor Pipeline Builds in DermatologyEight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Latest:
Advances in Treatment Resistant Port-Wine Birthmarks: Emerging Therapies and Future DirectionsExpect exciting news in the treatment of port-wine birthmarks, Kristen Marie Kelly, MD, told AAD Annual Meeting attendees.
Latest:
CBP/β-catenin Antagonists: A Safe and Novel Approach for Skin Rejuvenation and AgingTake a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.
Latest:
Further Research Needed to Study Link Between AD and ADHDResearchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.
Latest:
Roflumilast Patient Selection for Plaque Psoriasis TreatmentExperts describe roflumilast patient selection for plaque psoriasis treatment.
Latest:
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated MelanomaNivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Latest:
Looking Ahead to the 2023 ACMS MeetingThe ACMS president and scientific program chair share opportunities to discover innovations in Mohs surgery during this weekend’s meeting.
Latest:
Gut Microbiome Can Affect Radiation Cancer TreatmentThe overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.
Latest:
Clinical PresentationAndrew Alexis, MD, MPH, discusses how, in creating individualized treatment plans for vitiligo, clinicians must carefully consider the distinct challenges and response patterns associated with segmental vs nonsegmental forms, as segmental vitiligo tends to be more stable after initial progression but often more resistant to treatment, while nonsegmental vitiligo typically shows a more unpredictable course requiring ongoing management strategies.
Latest:
Hands-on Workshop Empowers Clinicians in Cosmetic DermatologyRobin Siperstein, MD, FAAD, shares practical tips in cosmetic dermatology at the 2024 SDPA Annual Summer Dermatology Meeting.
Latest:
Key Takeaways on the Management of Atopic DermatitisPanelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.
Latest:
Advancing Aesthetics: Innovations, Trends, and Patient-Centric Strategies in the Era of Weight Loss MedicationsDiscover insights from Gerry Muhle and Michael Somenek, MD, on regenerative aesthetics, weight-loss impacts, and trends shaping facial rejuvenation.
Latest:
Addressing Quality of Life Specifics Associated With Atopic Dermatitis and Skin of ColorZakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.
Latest:
Dermatologic differences in a diverse populationUnderstanding the difference in biology and clinical presentations of cutaneous conditions in different skin types is critical for health care professionals to treat a diverse population.
Latest:
Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque PsoriasisMiller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.
Latest:
The Importance of Collaboration Between Mohs Surgeons and UrologistsCaleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.
Latest:
Clinical Pearls: PDPA’s 5th Annual Keystone Dermatology ConferenceJamie Restivo, MPAS, PA-C, shares some insights from the 5th Annual Keystone Dermatology Conference held from October 17 to 19 in Philadelphia, Pennsylvania.
Latest:
Jeff Stark, MD: Discussing Bimzelx’s Efficacy and Future in Treating Inflammatory Skin DiseasesStark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.
Latest:
Key Takeaways For the Management of Plaque PsoriasisExperts in dermatology share closing thoughts on the management of plaque psoriasis.
Latest:
Frontline Forum Part 4: Improving Basal Cell Carcinoma ManagementIn the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.
Latest:
SFA-002 Shows Promise in Early Clinical Trial Psoriasis CohortsStefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
Latest:
Deucravacitinib: A Year in ReviewAs deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.
